ELVN Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
36.0M
-3.1%
37.2M
+33.7%
27.8M
-18.8%
34.3M
+36.6%
25.1M
R&D
28.0M
-3.4%
29.0M
+40.2%
20.7M
-2.6%
21.2M
+16.6%
18.2M
SG&A
8.0M
-2.3%
8.2M
+15.1%
7.1M
-45.3%
13.0M
+89.8%
6.9M
Operating Income
-36045000
+3.1%
-37209000
-33.7%
-27823000
+18.8%
-34285000
-36.6%
-25096000
EBITDA
-36032000
+3.1%
-37202000
-33.8%
-27809000
+18.8%
-34239000
-36.8%
-25034000
Net Income
-27703000
+14.7%
-32485000
-37.5%
-23627000
+20.4%
-29667000
-47.2%
-20148000
EPS (Basic)
$-0.36
+26.5%
$-0.49
-28.9%
$-0.38
+20.8%
$-0.48
-50.0%
$-0.32
EPS (Diluted)
$-0.36
+26.5%
$-0.49
-28.9%
$-0.38
+20.8%
$-0.48
-50.0%
$-0.32
Shares (Diluted)
78.0M
+17.8%
66.2M
+5.4%
62.8M
+0.6%
62.4M
+0.5%
62.1M
Enliven Therapeutics (ELVN) — Financials